Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 3, 2017, Pages 421-430.e6

  Younossi, Zobair M ^a   Stepanova, Maria ^b   Feld, Jordan ^c   Zeuzem, Stefan ^d   Sulkowski, Mark ^e   Foster, Graham R ^f   Mangia, Alessandra ^g   Charlton, Michael ^h   O'Leary, Jacqueline G ⁱ   Curry, Michael P ^j   Nader, Fatema ^b   Henry, Linda ^b   Hunt, Sharon ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE   (United States)

^c Toronto Liver Centre   (Canada)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^h INTERMOUNTAIN MEDICAL CENTER   (United States)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

DAA; Direct Acting Antivirals; PRO; Quality of Life

Indexed keywords

HEMOGLOBIN; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; VELPATASVIR;

AGE; ANXIETY DISORDER; ARTICLE; BODY MASS; CHRONIC LIVER DISEASE QUESTIONNAIRE HCV VERSION; COMORBIDITY; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; EMPLOYMENT STATUS; FATIGUE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HEPATITIS C; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; QUESTIONNAIRE; RACE DIFFERENCE; SEX DIFFERENCE; SHORT FORM 36; TREATMENT DURATION; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT SPECIFIC HEALTH PROBLEM; ADULT; AGED; COMBINATION DRUG THERAPY; COMPLICATION; FEMALE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROCEDURES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; CARBAMATES; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; RIBAVIRIN; SOFOSBUVIR; SURVEYS AND QUESTIONNAIRES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85013168403     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.10.037     Document Type: Article

References (23)

1. 1 Beste, L.A., Leipertz, S.L., Green, P.K., et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology 149 (2015), 1471–1482.
2. 2 Younossi, Z., Park, H., Henry, L., et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150 (2016), 1599–1608.
3. 3 Park, H., Adeyemi, A., Henry, L., et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat 22 (2015), 897–905.
4. 4 Younossi, Z., Henry, L., Systematic review: patient-reported outcomes in chronic hepatitis C—the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 41 (2015), 497–520.
5. 5 Younossi, Z., Henry, L., The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 46:Suppl 5 (2014), S186–S196.
6. 6 Younossi, Z.M., Stepanova, M., Nader, F., et al. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 42 (2015), 286–295.
7. 7 Feld, J.J., Jacobson, I.M., Hézode, C., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
8. 8 Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
9. 9 Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
10. 10 Pugh, R., Murray-Lyon, I.M., Dawson, J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973), 646–649.
11. 11 Ware, J.E. Jr., Sherbourne, C.D., The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992), 473–483.
12. 12 Webster, K., Cella, D., Yost, K., The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes, 1, 2003, 79.
13. 13 Younossi, Z.M., Guyatt, G., Kiwi, M., et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 45 (1999), 295–300.
14. 14 Younossi, Z.M., Stepanova, M., Henry, L., Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C. Value Health 19 (2016), 544–551.
15. 15 Reilly, M.C., Zbrozek, A.S., Dukes, E.M., The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4 (1993), 353–365.
16. 16 Stepanova, M., Nader, F., Cure, S., et al. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther 40 (2014), 676–685.
17. 17 Hsu, P.C., Federico, C.A., Krajden, M., et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 27 (2012), 149–157.
18. 18 Younossi, Z.M., Stepanova, M., Henry, L., et al. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 111 (2016), 808–816.
19. 19 Younossi, Z.M., Stepanova, M., Feld, J., et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol 65 (2016), 33–39.
20. 20 Younossi, Z.M., Stepanova, M., Sulkowski, M., et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results From ASTRAL-2 and -3 clinical trials. Clin Infect Dis 63 (2016), 1042–1048.
21. 21 Younossi, Z.M., Stepanova, M., Charlton, M., et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol 1 (2016), 122–132.
22. 22 Guyatt, G.H., Osoba, U., Wu, A.W., et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77 (2002), 371–383.
23. 23 Revicki, D., Hays, R.D., Cella, D., et al. Recommended methods for determining responsiveness and minimally important differences. J Clin Epidemiol 61 (2008), 102–109.